2020 Year in Review - Non–Small-Cell Lung Cancer

Skip to main content

Lung Cancer

NEJ009 Study: Gefitinib Alone versus Gefitinib + Chemotherapy for EGFR-Mutant NSCLC

Lung Cancer

GEOMETRY Mono-1 Study: Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC

Lung Cancer

IMpower150 Study: Atezolizumab in Combination with Bevacizumab and Chemotherapy in EGFR-Mutated NSCLC

Lung Cancer

Tarloxotinib in Patients with Advanced NSCLC Harboring an EGFR Exon 20 Insertion or HER2-Activating Mutation

Lung Cancer

Capmatinib + Nazartinib for EGFR-Mutant NSCLC

Lung Cancer

NSCLC Year in Review Introduction

Lung Cancer, Radiation Therapy

Upfront Local Radiation Therapy and First-Line TKI versus TKI Alone in Previously Untreated EGFR-Mutated Oligometastatic NSCLC

Lung Cancer

Selpercatinib Shows Antitumor Intracranial Activity in RET Fusion–Positive Patients with NSCLC and CNS Metastases

Lung Cancer

Sym015 Showed Similar Response Rate to MET TKI in Patients with METAmp/Ex14Δ NSCLC

Lung Cancer

RELAY Results: Patients with Exon 21 L858R or Exon 19 Deletion Mutations of EGFR Benefit from Ramucirumab + Erlotinib

1
2
3

Page 2 of 3
Results 11 - 20 of 30